Scientists reportedly have developed a therapy to decrease the extraordinarily high death rate associated with the SARS virus.
The International Herald Tribune said researchers told the journal Nature-Medicine they have solved the chemical riddle of why the severe acute respiratory syndrome virus causes such a deadly pneumonia.
During 2003, SARS killed nearly 800 people worldwide and resulted in the closing of airports, stores and schools across Asia.
Scientists studying mice say they've determined SARS is caused by a member of the coronavirus family. The virus interferes with a crucial enzyme pathway regulating body fluid balance, the report said. By blocking that enzyme system in the lungs, the virus allows liquid to leak into the lung's air sacs, making them boggy and inefficient.
Josef Penninger of the Austrian Academy of Science, lead author of the study, noted humans have the same enzyme system that's crucial in both species for blood pressure and fluid regulation.
Penninger said if the findings can be replicated in humans, the research may lead to a new treatment for SARS and other diseases causing death by allowing fluid into the lungs.
Copyright 2005 by United Press International
Related stories:
Discovery may help defang viruses
Researchers may be able to tinker with a single amino acid of an enzyme that helps viruses multiply to render them harmless, according to molecular biologists who say the discovery could pave the way for a fast and cheap method of making vaccines.
Setting the stage to find drugs against SARS
Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against severe acquired respiratory syndrome (SARS), the atypical pneumonia responsible for about 800 deaths worldwide since first recognized in late 2002. Researchers from Brookhaven's biology department and the National Synchrotron Light Source (NSLS) characterized a component of the virus that will be the target of new anti-SARS virus drugs.
Research leads to first treatment for drug-resistant HIV
Doctors have their first FDA-approved tool to treat drug-resistant HIV thanks to a new molecule created by a Purdue University researcher.
Atomic-resolution structure of a ribozyme yields insights into RNA catalysis and the origins of life
Which came first, nucleic acids or proteins? This question is molecular biology's version of the "chicken-or-the-egg" riddle. Genes made of nucleic acids (DNA or RNA) contain the instructions for making proteins, but enzymes made of proteins are needed to replicate genes. For those who try to understand how life originated, this once seemed an intractable paradox.
How to stop SARS viruses from reproducing
In times of the “bird flu” SARS seems to be no threat anymore. This notion is deceptive. Experts assume that viruses causing the severe acute respiratory syndrome SARS, or other related corona viruses, could re-emerge at any time and might pose a global public-health threat.
Enzyme study may lead to new SARS drugs
Scientists at the University of Illinois say a study of an enzyme that causes severe acute respiratory syndrome may lead to new drugs.
Enzyme inhibitors block replication of SARS virus
The study was conducted by researchers from Scripps Research; the Genomics Research Center, Academia Sinica, Taiwan; and the National Taiwan University. It is being published today in the journal
Chemistry and Biology.
Novel drug for SARS shows promise
A prototype drug created by researchers at the University of Illinois at Chicago shows promise in slowing replication of the virus responsible for severe acute respiratory syndrome, or SARS.
Currently, there are no effective antiviral agents or vaccines for SARS, which killed almost 800 people in an epidemic in 2002-2003.